THP-1 cell line

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Retrieved on: 
Monday, August 7, 2023

Leukemic cell growth was significantly reduced when treated with MT-401 OTS.

Key Points: 
  • Leukemic cell growth was significantly reduced when treated with MT-401 OTS.
  • Marker has established a cellular inventory of 8 lines manufactured from healthy donors, with ongoing efforts to further expand the inventory.
  • Marker anticipates that the first patient will be treated with MT-401 OTS during the first half of 2024.
  • If MT-401 OTS is successful in clinical trials, we will consider expanding the OTS multiTAA-specific T cell program to other indications with unmet medical needs,” concluded Dr. Vera.

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Retrieved on: 
Monday, June 26, 2023

MT-401 was designed to specifically target four different antigens (Survivin, PRAME, WT-1 and NY-ESO-1), which are upregulated in AML but have limited expression on normal cells.

Key Points: 
  • MT-401 was designed to specifically target four different antigens (Survivin, PRAME, WT-1 and NY-ESO-1), which are upregulated in AML but have limited expression on normal cells.
  • Given the promising responses in patients who are MRD+, Marker has been investigating clinical opportunities to further improve AML patient outcomes.
  • One such opportunity is to combine multiTAA-specific T cell therapy with agents that make cancer cells more visible to cancer killing cells.
  • These in vitro data demonstrate that administration of MT-401 following HMA infusion enhanced AML cell killing and could offer a new therapeutic option for AML patients post-HSCT.

ABLIC Launches the S-82L1/T1/U1/V1 Series, the Industry’s First (*1) 1-cell Battery Protection ICs with an Alarm Function

Retrieved on: 
Tuesday, November 8, 2022

ABLIC (President: Nobumasa Ishiai, head office: Minato-ku, Tokyo hereinafter ABLIC), a group company of MinebeaMitsumi Inc. today launched the S-82L1/T1/U1/V1 Series, the industrys first (*1) 1-cell battery protection ICs with an alarm function.

Key Points: 
  • ABLIC (President: Nobumasa Ishiai, head office: Minato-ku, Tokyo hereinafter ABLIC), a group company of MinebeaMitsumi Inc. today launched the S-82L1/T1/U1/V1 Series, the industrys first (*1) 1-cell battery protection ICs with an alarm function.
  • View the full release here: https://www.businesswire.com/news/home/20221107005007/en/
    ABLIC Launches the S-82L1/T1/U1/V1 Series, the Industrys First 1-cell Battery Protection ICs with an Alarm Function.
  • The Use of an Alarm Function Ensures Safe and Efficient Fast Charging without the Need for an AD Converter.
  • An overcharge detection voltage accuracy of 12mV places these ICs in the industrys high-accuracy top class!

ABLIC Launches the S-82Y1B Series of 1-cell Battery Protection ICs with the Upgraded World’s Highest (*1) Charge-discharge Overcurrent Detection Voltage Accuracy of ±0.5mV (*2)

Retrieved on: 
Tuesday, October 4, 2022

ABLIC (President: Nobumasa Ishiai, head office: Minato-ku, Tokyo hereinafter ABLIC), a group company of MinebeaMitsumi Inc., today launched the S-82Y1B Series of 1-cell battery protection ICs with the worlds highest (*1) charge-discharge overcurrent detection voltage accuracy of 0.5mV (*2).

Key Points: 
  • ABLIC (President: Nobumasa Ishiai, head office: Minato-ku, Tokyo hereinafter ABLIC), a group company of MinebeaMitsumi Inc., today launched the S-82Y1B Series of 1-cell battery protection ICs with the worlds highest (*1) charge-discharge overcurrent detection voltage accuracy of 0.5mV (*2).
  • View the full release here: https://www.businesswire.com/news/home/20221003005008/en/
    1-cell Battery Protection ICs with the Upgraded World's Highest Charge-Discharge Detection Voltage Accuracy of 0.5mV (Graphic: Business Wire)
    The new S-82Y1B Series of 1-cell lithium-ion battery protection ICs launched today is the upgraded version of our S-82P1 Series.
  • The new ICs (1) raise the charge-discharge overcurrent detection voltage accuracy from 0.75mV of the S-82P1 Series to the worlds highest accuracy of 0.5mV and suppress overcurrent detection variations while lowering current detection resistance, (2) provide three-stage discharge overcurrent protection, each stage of which ensures the industrys top class accuracy capable of reducing abnormal current to an even safer level, and (3) also boast the industrys top class overcharge detection voltage accuracy of 15mV.
  • The new ICs achieve the worlds highest charge-discharge overcurrent detection voltage accuracy of 0.5mV!

Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis

Retrieved on: 
Wednesday, September 7, 2022

The data was included in a poster presentation at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.

Key Points: 
  • The data was included in a poster presentation at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.
  • The latest preclinical data for AT-04 demonstrate potent binding to multiple types of systemic amyloid, as well as A, tau, and -synuclein aggregates, amyloid pathologies common in neurodegenerative disorders.
  • This binding of AT-04 to amyloid can induce phagocytosis, which is anticipated to lead to clearance of amyloid from the body.
  • The PAR-peptide mediates binding to all types of amyloid and the Fc stimulates the immune system to remove amyloid.

Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis

Retrieved on: 
Tuesday, September 6, 2022

The data was included in an oral presentation at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.

Key Points: 
  • The data was included in an oral presentation at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.
  • The use of amyloid-reactive CAR-M is an exciting novel approach to facilitate the macrophage-mediated removal of systemic amyloidosis, said Gregory Bell, MD, Chief Medical Officer at Attralus.
  • Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target recognition element.
  • CAR-M is a fusion of Attraluss pan-amyloid reactive p5 peptide as the amyloid binding moiety and human chimeric antigen receptor-macrophages.

Microbion Corporation Announces Data Highlighting In Vitro Activity of Pravibismane in NTM, including Activity Against NTM Causing Intracellular Infections, to be Presented at the Colorado Mycobacteria Conference 2022

Retrieved on: 
Wednesday, June 1, 2022

Pravibismane demonstrated an MIC of 0.3125 g/mL and 0.625 g/mL and against M. avium and M. abscessus intracellular infection in THP-1 cells, respectively.

Key Points: 
  • Pravibismane demonstrated an MIC of 0.3125 g/mL and 0.625 g/mL and against M. avium and M. abscessus intracellular infection in THP-1 cells, respectively.
  • As low as 2.5 g/mL pravibismane reduces intracellular M. avium 2285R (MDR) and M. abscessus 1153 (MDR) burden, superior to 20 g/mL rifampin and amikacin control drugs, respectively.
  • With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism.
  • Pravibismane exhibits broad-spectrum, potent in vitro activity against chronic respiratory infection-relevant pathogens and their biofilms including NTM, multidrug resistant P. aeruginosa and MRSA.

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

Retrieved on: 
Monday, May 2, 2022

Luxeptinib does not impede the assembly of the NLRP3-ASC complex but does potently inhibit three kinases phosphorylated in response to endotoxin.

Key Points: 
  • Luxeptinib does not impede the assembly of the NLRP3-ASC complex but does potently inhibit three kinases phosphorylated in response to endotoxin.
  • Luxeptinib also inhibits the release of TNF and IL-6 in response to activation of the TLR pathway without affecting the TLR/IRAK/MyD88 proteins.
  • Luxeptinib induced apoptosis in ibrutinib-resistant MCL cell lines, and in primary MCL cells luxeptinib downmodulated anti-apoptotic proteins Mcl-1 and Bcl-xL and reversed stromal cell survival effects.
  • Oral luxeptinib demonstrated strong antitumor activity in preclinical in vivo AML xenograft models but no myelosuppression or evidence of tissue damage in acute toxicology studies.